pharma · Schizophrenia · Alzheimer's Disease Psychosis · ACAD
Acadia Pharmaceuticals
Acadia Pharmaceuticals B.V.
Acadia Pharmaceuticals is a pharma organization headquartered in Indianapolis, USA. It trades on NYSE under ticker ACAD. Primary therapeutic focus areas include Schizophrenia, Alzheimer's Disease Psychosis, Parkinson Dis
Indianapolis, USA HQ
17 Employees
Public company Type
ACAD · NYSE Ticker
Company details
- Status
- Public
- HQ
- Indianapolis, USA
- Employees
- 17
- Programs
- 32
- Drugs
- 15
- Patents
- 77
ACP-211
Phase 2 · small molecule · Major Depressive Disorder (MDD)
ACP-211 for Major Depressive Disorder (MDD) is a Phase 2 program (small_molecule) at Acadia Pharmaceuticals B.V. with 1 ClinicalTrials.gov record(s).
Internal code ACP-211-002
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Acadia Pharmaceuticals B.V.
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Major Depressive Disorder (MDD)
- Status
- active
- Trials
- 1